Clinical trials have demonstrated that EGFR-tyrosine kinase inhibitor (TKI) therapy is highly effective for treating EGFRM NSCLC, resulting in high response rates and improved survival [2,3,4]. Here, EGFR is linked to non-small cell lung carcinoma.